Brett Baker

Safety, Tolerability, and Efficacy of Adjunctive Treatment with Topically Applied MBN-101 in Subjects with Moderate or Severe Diabetic Foot Infection (DFI): A Phase 1 Randomized, Double-Blind, Placebo-Controlled Study

Healing of diabetic foot ulcers is often compromised by microbial infections that are resistant to available antibiotics. New broad-spectrum topical antimicrobials may have the potential ...

Paul J. Kim , DPM, MS, FACFAS;

Brett Baker ;

Patricia A. McKernan ;

Brian Murphy ;

Benjamin Lipsky ;

12/11/2019

Two Phase 1 Clinical Studies Evaluating the Cumulative Irritation and Contact Sensitization on Intact and Abraded Skin of MBN-101, a Novel Antimicrobial Product in Development for Diabetic Foot Ulcer Infection

Background: MBN-101, a novel product in a new class of antimicrobial compounds with unique, broad-spectrum activity against bacteria and biofilm, is in clinical development for the t...

Brett Baker ;

Patricia A. McKernan ;

Margaret H. Butler ;

Russell K. Griggs ;

John R. Tkach ;

Daryl S. Paulson ;

08/12/2019